Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 12Meningioma 5Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma 1Carcinoid Tumor 1Advanced Lung Neuroendocrine Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 58130-nm albumin-bound paclitaxel 35Specimen Handling 26Fluorouracil 22Albumin-Bound Paclitaxel 22Magnetic Resonance Spectroscopy 21Leucovorin 21Irinotecan 21Oxaliplatin 19Biopsy 17Taxes 16pembrolizumab 15Cyclophosphamide 12Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8durvalumab 7Radiosurgery 7Nivolumab 7Carboplatin 7irinotecan sucrosofate 6dehydroftorafur 6Pemetrexed 6olaparib 5Radiotherapy 5Ipilimumab 5Erlotinib Hydrochloride 5Blood Specimen Collection 5trastuzumab deruxtecan 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × lutetium Lu 177 dotatate × 90 days × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡